Using recursive partitioning approach to select tumor‐associated antigens in immunodiagnosis of gastric adenocarcinoma

The present study aimed to select anti‐tumor‐associated antigen (TAA) autoantibodies as biomarkers in the immunodiagnosis of gastric adenocarcinoma (GAC) by the recursive partitioning approach (RPA) and further construct and evaluate a predictive model. A case‐control study was designed including 40...

Full description

Saved in:
Bibliographic Details
Published inCancer science Vol. 110; no. 6; pp. 1829 - 1841
Main Authors Qin, Jiejie, Wang, Shuaibing, Shi, Jianxiang, Ma, Yan, Wang, Keyan, Ye, Hua, Zhang, Xiaojun, Wang, Peng, Wang, Xiao, Song, Chunhua, Dai, Liping, Wang, Kaijuan, Jiang, Binghua, Zhang, Jianying
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.06.2019
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The present study aimed to select anti‐tumor‐associated antigen (TAA) autoantibodies as biomarkers in the immunodiagnosis of gastric adenocarcinoma (GAC) by the recursive partitioning approach (RPA) and further construct and evaluate a predictive model. A case‐control study was designed including 407 GAC patients as the case group and 407 normal controls. In addition, 67 serial serum samples from 25 GAC patients were collected at different time points before and after gastrectomy treatment. Autoantibodies against 14 TAA were measured in sera from all subjects by enzyme immunoassay. Finally, RPA resulted in the selection of nine‐panel TAA (c‐Myc, p16, HSPD1, PTEN, p53, NPM1, ENO1, p62, HCC1.4) from all detected TAA in the case‐control study; the classification tree based on this nine‐TAA panel had area under curve (AUC) of 0.857, sensitivity of 71.5% and specificity of 71.3%; The optimal panel also can identify GAC patients at an early stage from normal individuals, with AUC of 0.737, sensitivity of 64.9% and specificity of 70.5%. However, frequencies of the nine autoantibodies showed no correlation with GAC stage, tumor size, lymphatic metastasis or differentiation. GAC patients positive for more than two autoantibodies in the nine‐TAA panel had a worse prognosis than that of the GAC patients positive for no or one antibody. Titers of 10 autoantibodies in serial serum samples were significantly higher in GAC patients after surgical resection than before. In conclusion, this study showed that the panel of nine multiple TAAs could enhance the detection of anti‐TAA antibodies in GAC, and may be potential prognostic biomarkers in GAC. Recursive partitioning approach (RPA) is a powerful method for selecting markers in cancer and a panel selected by RPA showed high diagnostic values for gastric adenocarcinoma. Antibody levels showed no correlation with tumor stage, size, or differentiation. Certain anti‐TAA antibodies increased after gastrectomy in gastric adenocarcinoma sera.
AbstractList The present study aimed to select anti‐tumor‐associated antigen (TAA) autoantibodies as biomarkers in the immunodiagnosis of gastric adenocarcinoma (GAC) by the recursive partitioning approach (RPA) and further construct and evaluate a predictive model. A case‐control study was designed including 407 GAC patients as the case group and 407 normal controls. In addition, 67 serial serum samples from 25 GAC patients were collected at different time points before and after gastrectomy treatment. Autoantibodies against 14 TAA were measured in sera from all subjects by enzyme immunoassay. Finally, RPA resulted in the selection of nine‐panel TAA (c‐Myc, p16, HSPD1, PTEN, p53, NPM1, ENO1, p62, HCC1.4) from all detected TAA in the case‐control study; the classification tree based on this nine‐TAA panel had area under curve (AUC) of 0.857, sensitivity of 71.5% and specificity of 71.3%; The optimal panel also can identify GAC patients at an early stage from normal individuals, with AUC of 0.737, sensitivity of 64.9% and specificity of 70.5%. However, frequencies of the nine autoantibodies showed no correlation with GAC stage, tumor size, lymphatic metastasis or differentiation. GAC patients positive for more than two autoantibodies in the nine‐TAA panel had a worse prognosis than that of the GAC patients positive for no or one antibody. Titers of 10 autoantibodies in serial serum samples were significantly higher in GAC patients after surgical resection than before. In conclusion, this study showed that the panel of nine multiple TAAs could enhance the detection of anti‐TAA antibodies in GAC, and may be potential prognostic biomarkers in GAC. Recursive partitioning approach (RPA) is a powerful method for selecting markers in cancer and a panel selected by RPA showed high diagnostic values for gastric adenocarcinoma. Antibody levels showed no correlation with tumor stage, size, or differentiation. Certain anti‐TAA antibodies increased after gastrectomy in gastric adenocarcinoma sera.
The present study aimed to select anti-tumor-associated antigen (TAA) autoantibodies as biomarkers in the immunodiagnosis of gastric adenocarcinoma (GAC) by the recursive partitioning approach (RPA) and further construct and evaluate a predictive model. A case-control study was designed including 407 GAC patients as the case group and 407 normal controls. In addition, 67 serial serum samples from 25 GAC patients were collected at different time points before and after gastrectomy treatment. Autoantibodies against 14 TAA were measured in sera from all subjects by enzyme immunoassay. Finally, RPA resulted in the selection of nine-panel TAA (c-Myc, p16, HSPD1, PTEN, p53, NPM1, ENO1, p62, HCC1.4) from all detected TAA in the case-control study; the classification tree based on this nine-TAA panel had area under curve (AUC) of 0.857, sensitivity of 71.5% and specificity of 71.3%; The optimal panel also can identify GAC patients at an early stage from normal individuals, with AUC of 0.737, sensitivity of 64.9% and specificity of 70.5%. However, frequencies of the nine autoantibodies showed no correlation with GAC stage, tumor size, lymphatic metastasis or differentiation. GAC patients positive for more than two autoantibodies in the nine-TAA panel had a worse prognosis than that of the GAC patients positive for no or one antibody. Titers of 10 autoantibodies in serial serum samples were significantly higher in GAC patients after surgical resection than before. In conclusion, this study showed that the panel of nine multiple TAAs could enhance the detection of anti-TAA antibodies in GAC, and may be potential prognostic biomarkers in GAC.
The present study aimed to select anti‐tumor‐associated antigen ( TAA ) autoantibodies as biomarkers in the immunodiagnosis of gastric adenocarcinoma ( GAC ) by the recursive partitioning approach ( RPA ) and further construct and evaluate a predictive model. A case‐control study was designed including 407 GAC patients as the case group and 407 normal controls. In addition, 67 serial serum samples from 25 GAC patients were collected at different time points before and after gastrectomy treatment. Autoantibodies against 14 TAA were measured in sera from all subjects by enzyme immunoassay. Finally, RPA resulted in the selection of nine‐panel TAA (c‐Myc, p16, HSPD 1, PTEN , p53, NPM 1, ENO 1, p62, HCC 1.4) from all detected TAA in the case‐control study; the classification tree based on this nine‐ TAA panel had area under curve ( AUC ) of 0.857, sensitivity of 71.5% and specificity of 71.3%; The optimal panel also can identify GAC patients at an early stage from normal individuals, with AUC of 0.737, sensitivity of 64.9% and specificity of 70.5%. However, frequencies of the nine autoantibodies showed no correlation with GAC stage, tumor size, lymphatic metastasis or differentiation. GAC patients positive for more than two autoantibodies in the nine‐ TAA panel had a worse prognosis than that of the GAC patients positive for no or one antibody. Titers of 10 autoantibodies in serial serum samples were significantly higher in GAC patients after surgical resection than before. In conclusion, this study showed that the panel of nine multiple TAAs could enhance the detection of anti‐ TAA antibodies in GAC , and may be potential prognostic biomarkers in GAC .
The present study aimed to select anti-tumor-associated antigen (TAA) autoantibodies as biomarkers in the immunodiagnosis of gastric adenocarcinoma (GAC) by the recursive partitioning approach (RPA) and further construct and evaluate a predictive model. A case-control study was designed including 407 GAC patients as the case group and 407 normal controls. In addition, 67 serial serum samples from 25 GAC patients were collected at different time points before and after gastrectomy treatment. Autoantibodies against 14 TAA were measured in sera from all subjects by enzyme immunoassay. Finally, RPA resulted in the selection of nine-panel TAA (c-Myc, p16, HSPD1, PTEN, p53, NPM1, ENO1, p62, HCC1.4) from all detected TAA in the case-control study; the classification tree based on this nine-TAA panel had area under curve (AUC) of 0.857, sensitivity of 71.5% and specificity of 71.3%; The optimal panel also can identify GAC patients at an early stage from normal individuals, with AUC of 0.737, sensitivity of 64.9% and specificity of 70.5%. However, frequencies of the nine autoantibodies showed no correlation with GAC stage, tumor size, lymphatic metastasis or differentiation. GAC patients positive for more than two autoantibodies in the nine-TAA panel had a worse prognosis than that of the GAC patients positive for no or one antibody. Titers of 10 autoantibodies in serial serum samples were significantly higher in GAC patients after surgical resection than before. In conclusion, this study showed that the panel of nine multiple TAAs could enhance the detection of anti-TAA antibodies in GAC, and may be potential prognostic biomarkers in GAC.The present study aimed to select anti-tumor-associated antigen (TAA) autoantibodies as biomarkers in the immunodiagnosis of gastric adenocarcinoma (GAC) by the recursive partitioning approach (RPA) and further construct and evaluate a predictive model. A case-control study was designed including 407 GAC patients as the case group and 407 normal controls. In addition, 67 serial serum samples from 25 GAC patients were collected at different time points before and after gastrectomy treatment. Autoantibodies against 14 TAA were measured in sera from all subjects by enzyme immunoassay. Finally, RPA resulted in the selection of nine-panel TAA (c-Myc, p16, HSPD1, PTEN, p53, NPM1, ENO1, p62, HCC1.4) from all detected TAA in the case-control study; the classification tree based on this nine-TAA panel had area under curve (AUC) of 0.857, sensitivity of 71.5% and specificity of 71.3%; The optimal panel also can identify GAC patients at an early stage from normal individuals, with AUC of 0.737, sensitivity of 64.9% and specificity of 70.5%. However, frequencies of the nine autoantibodies showed no correlation with GAC stage, tumor size, lymphatic metastasis or differentiation. GAC patients positive for more than two autoantibodies in the nine-TAA panel had a worse prognosis than that of the GAC patients positive for no or one antibody. Titers of 10 autoantibodies in serial serum samples were significantly higher in GAC patients after surgical resection than before. In conclusion, this study showed that the panel of nine multiple TAAs could enhance the detection of anti-TAA antibodies in GAC, and may be potential prognostic biomarkers in GAC.
Author Wang, Peng
Dai, Liping
Shi, Jianxiang
Ye, Hua
Wang, Shuaibing
Zhang, Jianying
Jiang, Binghua
Song, Chunhua
Qin, Jiejie
Wang, Kaijuan
Zhang, Xiaojun
Wang, Keyan
Wang, Xiao
Ma, Yan
AuthorAffiliation 2 Third Affiliated Hospital of Zhengzhou University Zhengzhou China
3 Henan Academy of Medical and Pharmaceutical Sciences Zhengzhou University Zhengzhou China
1 Department of Epidemiology and Health Statistics & Henan Key Laboratory for Tumor Epidemiology College of Public Health Zhengzhou University Zhengzhou China
AuthorAffiliation_xml – name: 3 Henan Academy of Medical and Pharmaceutical Sciences Zhengzhou University Zhengzhou China
– name: 1 Department of Epidemiology and Health Statistics & Henan Key Laboratory for Tumor Epidemiology College of Public Health Zhengzhou University Zhengzhou China
– name: 2 Third Affiliated Hospital of Zhengzhou University Zhengzhou China
Author_xml – sequence: 1
  givenname: Jiejie
  surname: Qin
  fullname: Qin, Jiejie
  organization: Zhengzhou University
– sequence: 2
  givenname: Shuaibing
  surname: Wang
  fullname: Wang, Shuaibing
  organization: Third Affiliated Hospital of Zhengzhou University
– sequence: 3
  givenname: Jianxiang
  surname: Shi
  fullname: Shi, Jianxiang
  organization: Zhengzhou University
– sequence: 4
  givenname: Yan
  surname: Ma
  fullname: Ma, Yan
  organization: Zhengzhou University
– sequence: 5
  givenname: Keyan
  surname: Wang
  fullname: Wang, Keyan
  organization: Zhengzhou University
– sequence: 6
  givenname: Hua
  surname: Ye
  fullname: Ye, Hua
  organization: Zhengzhou University
– sequence: 7
  givenname: Xiaojun
  surname: Zhang
  fullname: Zhang, Xiaojun
  organization: Zhengzhou University
– sequence: 8
  givenname: Peng
  surname: Wang
  fullname: Wang, Peng
  organization: Zhengzhou University
– sequence: 9
  givenname: Xiao
  surname: Wang
  fullname: Wang, Xiao
  organization: Zhengzhou University
– sequence: 10
  givenname: Chunhua
  orcidid: 0000-0001-6028-5923
  surname: Song
  fullname: Song, Chunhua
  organization: Zhengzhou University
– sequence: 11
  givenname: Liping
  surname: Dai
  fullname: Dai, Liping
  organization: Zhengzhou University
– sequence: 12
  givenname: Kaijuan
  surname: Wang
  fullname: Wang, Kaijuan
  organization: Zhengzhou University
– sequence: 13
  givenname: Binghua
  surname: Jiang
  fullname: Jiang, Binghua
  organization: Zhengzhou University
– sequence: 14
  givenname: Jianying
  orcidid: 0000-0003-2938-9526
  surname: Zhang
  fullname: Zhang, Jianying
  email: jianyingzhang@hotmail.com
  organization: Zhengzhou University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30950146$$D View this record in MEDLINE/PubMed
BookMark eNp1kc9uFSEUxompsX904QsYEje6mBYGBu5sTJob_yVNXGjXhAFmepoZGIFp7c5H6DP2SeT23hptlM0hh9_58h2-Q7Tng3cIvaTkmJZzYnQ6ppxQ9gQdUMbbShIi9u7vsmoJq_fRYUqXhDDBW_4M7TPSNoRycYB-nCfwA47OLDHBlcOzjhkyBL9p63mOQZsLnANObnQm47xMId79vNUpBQM6O4u1zzA4nzB4DNO0-GBBDz4kSDj0eNApRzBYW-eD0dGAD5N-jp72ekzuxa4eofMP77-tP1VnXz5-Xp-eVaZhjFVt1_aNWdFWctGKvrGit6RhhFhJ2q5vpJDGcMq6smsv60Zy07HOWEtWZVm5Ykfo3VZ3XrrJWeN8jnpUc4RJxxsVNKi_XzxcqCFcKdGUL6o3Am92AjF8X1zKaoJk3Dhq78KSVF0TLlailIK-foRehiX6sl6huBSsLmEU6tWfjn5beQilACdbwMSQUnS9MpD1JpNiEEZFidrErkrs6j72MvH20cSD6L_Ynfo1jO7m_6Ban37dTvwCqdG_Pw
CitedBy_id crossref_primary_10_1007_s12325_020_01571_z
crossref_primary_10_3389_fimmu_2021_728853
crossref_primary_10_1038_s41598_024_60544_2
crossref_primary_10_14309_ctg_0000000000000284
crossref_primary_10_1080_14737159_2023_2232298
crossref_primary_10_1111_cas_14732
crossref_primary_10_1186_s12953_021_00184_w
crossref_primary_10_1038_s41416_024_02781_w
crossref_primary_10_3390_cancers16173019
crossref_primary_10_3390_biomedicines10010097
crossref_primary_10_3389_fimmu_2021_724741
crossref_primary_10_3389_fgene_2022_872253
crossref_primary_10_1002_ijc_33165
crossref_primary_10_1080_2162402X_2019_1682382
crossref_primary_10_1016_j_trac_2024_117753
crossref_primary_10_1007_s00432_023_04732_z
crossref_primary_10_3389_fonc_2021_733680
crossref_primary_10_2174_1386207326666230419080531
crossref_primary_10_1186_s12935_023_03107_1
crossref_primary_10_1002_ags3_12910
crossref_primary_10_1364_OPTCON_462176
crossref_primary_10_1111_cas_15021
crossref_primary_10_3390_cancers12051271
crossref_primary_10_3389_fimmu_2021_658922
crossref_primary_10_1016_j_smim_2020_101388
crossref_primary_10_3390_cancers13040813
Cites_doi 10.1158/1055-9965.EPI-17-0238
10.1158/1078-0432.CCR-12-0281
10.4049/jimmunol.166.1.678
10.1038/srep25467
10.1007/s12328-017-0749-9
10.2174/092986712803988910
10.1002/cncr.22265
10.1074/jbc.M114.565796
10.1002/ijc.27667
10.1111/dote.12206
10.1080/2162402X.2018.1452582
10.1002/ags3.12179
10.1207/S15324796ABM2603_02
10.1158/1078-0432.CCR-08-1086
10.4143/crt.2016.089
10.1016/j.cell.2012.03.003
10.1084/jem.189.7.1101
10.1186/2162-3619-2-15
10.1586/14737159.2015.1035713
10.1002/path.1288
10.3322/caac.21262
10.1158/0008-5472.CAN-05-3389
10.7717/peerj.3585
10.1007/s00268-008-9821-4
10.1016/S0161-5890(02)00026-3
10.1007/s11060-017-2716-1
10.1002/ijc.28807
10.1128/MCB.19.2.1262
10.1586/erm.10.12
10.1111/cas.13158
10.1158/0008-5472.CAN-03-2646
10.1007/s13277-015-4472-1
10.1002/pros.23217
10.1515/sagmb-2013-0016
10.1073/pnas.111153698
10.1007/s13277-014-1819-y
10.1074/mcp.M115.051250
10.1111/j.1600-065X.2008.00611.x
10.1590/S0100-879X2003000300008
ContentType Journal Article
Copyright 2019 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Copyright John Wiley & Sons, Inc. Jun 2019
Copyright_xml – notice: 2019 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
– notice: 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
– notice: Copyright John Wiley & Sons, Inc. Jun 2019
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1111/cas.14013
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
CrossRef

Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate QIN et al
EISSN 1349-7006
EndPage 1841
ExternalDocumentID PMC6550128
30950146
10_1111_cas_14013
CAS14013
Genre article
Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: The National Science and Technology Major Project of China
  funderid: 2018ZX10302205
– fundername: Major Project of Science and Technology in Henan Province
  funderid: 16110311400
– fundername: Program of Natural Science Foundation of Henan Province; and the Key Project of Tackling Key Problems in Science and Technology of Henan Province
  funderid: 182300410009; 182102310110; 192102310042
– fundername: Program of Natural Science Foundation of Henan Province; and the Key Project of Tackling Key Problems in Science and Technology of Henan Province
  grantid: 182300410009
– fundername: The National Science and Technology Major Project of China
  grantid: 2018ZX10302205
– fundername: Major Project of Science and Technology in Henan Province
  grantid: 16110311400
– fundername: Program of Natural Science Foundation of Henan Province; and the Key Project of Tackling Key Problems in Science and Technology of Henan Province
  grantid: 182102310110
– fundername: Program of Natural Science Foundation of Henan Province; and the Key Project of Tackling Key Problems in Science and Technology of Henan Province
  grantid: 192102310042
– fundername: Program of Natural Science Foundation of Henan Province; and the Key Project of Tackling Key Problems in Science and Technology of Henan Province
  grantid: 182300410009; 182102310110; 192102310042
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
1OC
24P
29B
2WC
31~
36B
3O-
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52W
52X
53G
5GY
5HH
5LA
5VS
66C
7.U
702
7PT
8-0
8-1
8-3
8-4
8-5
8FE
8FH
8UM
930
A01
A03
AAHHS
AAZKR
ABCQN
ABEML
ACCFJ
ACCMX
ACSCC
ACXQS
ADBBV
ADKYN
ADPDF
ADZMN
ADZOD
AEEZP
AENEX
AEQDE
AFBPY
AFEBI
AFFNX
AFKRA
AFPKN
AFZJQ
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AOIJS
AVUZU
BAWUL
BBNVY
BCNDV
BENPR
BFHJK
BHPHI
BY8
CAG
CCPQU
COF
CS3
D-6
D-7
D-E
D-F
DIK
DR2
DU5
E3Z
EBS
EJD
EMB
EMOBN
EX3
F00
F01
F04
F5P
FIJ
GODZA
GROUPED_DOAJ
HCIFZ
HF~
HOLLA
HYE
HZI
HZ~
IAO
IHR
IPNFZ
ITC
IX1
J0M
K.9
K48
KQ8
LC2
LC3
LH4
LK8
LP6
LP7
LW6
M7P
MK4
N04
N05
N9A
O9-
OIG
OK1
OVD
P2P
P2X
P2Z
P4B
P4D
PIMPY
PROAC
Q11
ROL
RPM
RX1
SJN
SUPJJ
SV3
TEORI
UB1
W8V
WIN
WOW
WQJ
WRC
WXI
X7M
XG1
ZXP
~IA
~WT
7X7
88E
8FI
8FJ
AAFWJ
AAYXX
ABUWG
CITATION
FYUFA
HMCUK
M1P
PHGZM
PHGZT
PSQYO
UKHRP
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
3V.
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c5333-9b9f5c81974696f5d6fd05300d709bf5767cc413b134f72574cb3bcdd08364783
IEDL.DBID 7X7
ISSN 1347-9032
1349-7006
IngestDate Thu Aug 21 13:56:17 EDT 2025
Fri Jul 11 11:05:39 EDT 2025
Wed Aug 13 08:37:29 EDT 2025
Mon Jul 21 05:44:01 EDT 2025
Tue Jul 01 01:31:06 EDT 2025
Thu Apr 24 22:58:47 EDT 2025
Wed Jan 22 16:41:10 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords recursive partitioning approach
autoantibody
gastric adenocarcinoma
tumor-associated antigen
biomarker
Language English
License Attribution-NonCommercial-NoDerivs
2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5333-9b9f5c81974696f5d6fd05300d709bf5767cc413b134f72574cb3bcdd08364783
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-6028-5923
0000-0003-2938-9526
OpenAccessLink https://www.proquest.com/docview/2247632903?pq-origsite=%requestingapplication%
PMID 30950146
PQID 2247632903
PQPubID 4378882
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6550128
proquest_miscellaneous_2204686220
proquest_journals_2247632903
pubmed_primary_30950146
crossref_citationtrail_10_1111_cas_14013
crossref_primary_10_1111_cas_14013
wiley_primary_10_1111_cas_14013_CAS14013
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate June 2019
PublicationDateYYYYMMDD 2019-06-01
PublicationDate_xml – month: 06
  year: 2019
  text: June 2019
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Tokyo
– name: Hoboken
PublicationTitle Cancer science
PublicationTitleAlternate Cancer Sci
PublicationYear 2019
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
References 2017; 5
2010; 10
2004; 64
2013; 2
2016; 76
2012; 19
2012; 18
2018; 40
2011; 58
2008; 222
2008; 2
2016; 37
2003; 12
2018; 7
2018; 2
1999; 19
2015; 136
2013; 12
2006; 66
2018; 137
2003; 9
1984
2016; 48
2003; 200
2007; 23
2014; 289
2001; 98
2002; 38
2001; 166
2017; 20
2015; 15
2017; 26
2008; 14
2003; 36
1999; 189
2012; 149
2016; 15
1999; 5
2017; 108
2009; 33
2016; 6
2015; 28
2017; 10
2015; 65
1983; 43
2003; 26
2018
2014; 35
2013; 132
2006; 107
Park JM (e_1_2_7_5_1) 2008; 2
e_1_2_7_9_1
e_1_2_7_19_1
e_1_2_7_15_1
e_1_2_7_41_1
Lawniczak M (e_1_2_7_30_1) 2007; 23
e_1_2_7_13_1
e_1_2_7_43_1
e_1_2_7_11_1
e_1_2_7_45_1
e_1_2_7_47_1
e_1_2_7_26_1
e_1_2_7_49_1
e_1_2_7_28_1
Hess KR (e_1_2_7_17_1) 1999; 5
Li Y (e_1_2_7_7_1) 2011; 58
e_1_2_7_50_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_33_1
e_1_2_7_21_1
e_1_2_7_35_1
e_1_2_7_39_1
e_1_2_7_4_1
Dillman RO (e_1_2_7_37_1) 1983; 43
Breiman L (e_1_2_7_20_1) 1984
e_1_2_7_8_1
Zhao J (e_1_2_7_6_1) 2017; 20
Koziol JA (e_1_2_7_18_1) 2003; 9
e_1_2_7_16_1
e_1_2_7_40_1
e_1_2_7_2_1
Gu XY (e_1_2_7_3_1) 2018; 40
e_1_2_7_14_1
e_1_2_7_42_1
e_1_2_7_12_1
e_1_2_7_44_1
e_1_2_7_10_1
e_1_2_7_46_1
e_1_2_7_48_1
e_1_2_7_27_1
e_1_2_7_29_1
e_1_2_7_51_1
e_1_2_7_24_1
e_1_2_7_32_1
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_36_1
e_1_2_7_38_1
Zhang JY (e_1_2_7_23_1) 2003; 12
References_xml – volume: 33
  start-page: 272
  year: 2009
  end-page: 277
  article-title: Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma
  publication-title: World J Surg
– volume: 15
  start-page: 829
  year: 2015
  end-page: 852
  article-title: Tumor associated antigens or anti‐TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta‐analysis
  publication-title: Expert Rev Mol Diagn
– volume: 2
  start-page: 15
  year: 2013
  end-page: 21
  article-title: Autoantibodies to tumor‐associated antigens as biomarkers in human hepatocellular carcinoma (HCC)
  publication-title: Exp Hematol Oncol
– volume: 5
  start-page: 3403
  year: 1999
  end-page: 3410
  article-title: Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma
  publication-title: Clin Cancer Res
– volume: 64
  start-page: 2205
  year: 2004
  end-page: 2211
  article-title: Surgical removal of primary tumor reverses tumor‐induced immunosuppression despite the presence of metastatic disease
  publication-title: Cancer Res
– year: 2018
– volume: 12
  start-page: 637
  year: 2013
  end-page: 652
  article-title: Identifying clusters in genomics data by recursive partitioning
  publication-title: Stat Appl Genet Mol Biol
– volume: 28
  start-page: 371
  year: 2015
  end-page: 379
  article-title: Detection of autoantibodies to a panel of tumor‐associated antigens for the diagnosis values of gastric cardia adenocarcinoma
  publication-title: Dis Esophagus
– volume: 58
  start-page: 2166
  year: 2011
  end-page: 2170
  article-title: Predictive value of serum CEA, CA19‐9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer
  publication-title: Hepatogastroenterology
– volume: 15
  start-page: 614
  year: 2016
  end-page: 623
  article-title: Identification of serum biomarkers for gastric cancer diagnosis using a human proteome microarray
  publication-title: Mol Cell Proteomics
– volume: 98
  start-page: 6730
  year: 2001
  end-page: 6735
  article-title: Recursive partitioning for tumor classification with gene expression microarray data
  publication-title: Proc Natl Acad Sci USA
– volume: 137
  start-page: 289
  year: 2018
  end-page: 293
  article-title: Recursive partitioning analysis is predictive of overall survival for patients undergoing spine stereotactic radiosurgery
  publication-title: J Neurooncol
– volume: 6
  start-page: 254
  year: 2016
  end-page: 267
  article-title: Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer
  publication-title: Sci Rep
– volume: 2
  start-page: 137
  year: 2008
  end-page: 144
  article-title: Current approaches to gastric cancer in Korea
  publication-title: Gastrointest Cancer Res
– volume: 20
  start-page: 47
  year: 2017
  end-page: 52
  article-title: Establishment of risk evaluation model of peritoneal metastasis in gastric cancer and its predictive value
  publication-title: Chin J Gastrointest Surg
– volume: 37
  start-page: 8709
  year: 2016
  end-page: 8714
  article-title: A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with cervical cancer
  publication-title: Tumour Biol
– volume: 200
  start-page: 39
  year: 2003
  end-page: 46
  article-title: Tumour suppressor gene expression correlates with gastric cancer prognosis
  publication-title: J Pathol
– volume: 7
  start-page: e1452582
  year: 2018
  article-title: Using a panel of multiple tumor‐associated antigens to enhance autoantibody detection for immunodiagnosis of gastric cancer
  publication-title: Oncoimmunology
– volume: 76
  start-page: 1375
  year: 2016
  end-page: 1386
  article-title: Using serological proteome analysis to identify serum anti‐nucleophosmin 1 autoantibody as a potential biomarker in European‐American and African‐American patients with prostate cancer
  publication-title: Prostate
– volume: 10
  start-page: 357
  year: 2017
  end-page: 360
  article-title: Negative conversion of high serum p53 antibody titers in a patient with gastric cancer at 31 months after surgery
  publication-title: Clin J Gastroenterol
– volume: 23
  start-page: 192
  year: 2007
  end-page: 195
  article-title: Serum anti‐p53 antibodies in gastric cancer patients
  publication-title: Pol Merkur Lekarski
– volume: 38
  start-page: 981
  year: 2002
  end-page: 987
  article-title: Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non‐functional p53
  publication-title: Mol Immunol
– volume: 2
  start-page: 266
  year: 2018
  end-page: 273
  article-title: p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma
  publication-title: Ann Gastroenterol Surg
– volume: 19
  start-page: 5705
  year: 2012
  end-page: 5725
  article-title: Natural product MDM2 inhibitors: anticancer activity and mechanisms of action
  publication-title: Curr Med Chem
– volume: 43
  start-page: 417
  year: 1983
  end-page: 421
  article-title: Statistical approach to immunosuppression classification using lymphocyte surface‐markers and functional assays
  publication-title: Can Res
– volume: 18
  start-page: 5617
  year: 2012
  end-page: 5627
  article-title: 14‐3‐3zeta, a novel androgen‐responsive gene, is upregulated in prostate cancer and promotes prostate cancer cell proliferation and survival
  publication-title: Clin Cancer Res
– volume: 48
  start-page: 436
  year: 2016
  end-page: 450
  article-title: Community of Population‐Based Regional Cancer Registries. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013
  publication-title: Cancer Res Treat
– volume: 9
  start-page: 5120
  year: 2003
  end-page: 5126
  article-title: Recursive partitioning as an approach to selection of immune markers for tumor diagnosis
  publication-title: Clin Cancer Res
– volume: 19
  start-page: 1262
  year: 1999
  end-page: 1270
  article-title: A family of insulin‐like growth factor II mRNA‐binding proteins represses translation in late development
  publication-title: Mol Cell Biol
– volume: 26
  start-page: 172
  year: 2003
  end-page: 181
  article-title: Classification and regression tree analysis in public health: methodological review and comparison with logistic regression
  publication-title: Ann Behav Med
– volume: 35
  start-page: 6311
  year: 2014
  end-page: 6317
  article-title: Overexpression of HCC1/CAPERα may play a role in lung cancer carcinogenesis
  publication-title: Tumour Biol
– volume: 65
  start-page: 87
  year: 2015
  end-page: 108
  article-title: Global cancer statistics, 2012
  publication-title: CA Cancer J Clin
– volume: 136
  start-page: 2243
  year: 2015
  end-page: 2252
  article-title: Systematic review: serum autoantibodies in the early detection of gastric cancer
  publication-title: Int J Cancer
– start-page: 18
  year: 1984
  end-page: 58
– volume: 14
  start-page: 6487
  year: 2008
  end-page: 6495
  article-title: Identification of a novel tumor‐associated antigen, cadherin 3/P‐cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers
  publication-title: Clin Cancer Res
– volume: 66
  start-page: 6
  year: 2006
  end-page: 9
  article-title: Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer
  publication-title: Can Res
– volume: 222
  start-page: 328
  year: 2008
  end-page: 340
  article-title: Autoantibodies to tumor‐associated antigens: reporters from the immune system
  publication-title: Immunol Rev
– volume: 189
  start-page: 1101
  year: 1999
  end-page: 1110
  article-title: A novel cytoplasmic protein with RNA‐binding motifs is an autoantigen in human hepatocellular carcinoma
  publication-title: J Exp Med
– volume: 132
  start-page: 137
  year: 2013
  end-page: 147
  article-title: Tumor‐associated autoantibody signature for the early detection of gastric cancer
  publication-title: Int J Cancer
– volume: 166
  start-page: 678
  year: 2001
  end-page: 689
  article-title: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer
  publication-title: J Immunol
– volume: 10
  start-page: 321
  year: 2010
  end-page: 328
  article-title: Autoantibodies to tumor‐associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors
  publication-title: Expert Rev Mol Diagn
– volume: 40
  start-page: 241
  year: 2018
  end-page: 246
  article-title: Incidence and mortality of cervical cancer in China, 2014
  publication-title: Chin J Oncol
– volume: 26
  start-page: 1564
  year: 2017
  end-page: 1574
  article-title: The prevalence of cancer‐associated autoantibodies in patients with gastric cancer and progressive grades of premalignant lesions
  publication-title: Cancer Epidemiol Biomarkers Prev
– volume: 149
  start-page: 22
  year: 2012
  end-page: 35
  article-title: MYC on the path to cancer
  publication-title: Cell
– volume: 107
  start-page: 2417
  year: 2006
  end-page: 2424
  article-title: Hsp60 and Hsp10 down‐regulation predicts bronchial epithelial carcinogenesis in smokers with chronic obstructive pulmonary disease
  publication-title: Cancer
– volume: 12
  start-page: 136
  year: 2003
  end-page: 143
  article-title: Enhancement of antibody detection in cancer using panel of recombinant tumor‐associated antigens
  publication-title: Cancer Epidemiol Biomarkers Prev
– volume: 5
  start-page: e3585
  year: 2017
  article-title: Mutational analysis of driver genes with tumor suppressive and oncogenic roles in gastric cancer
  publication-title: PeerJ
– volume: 36
  start-page: 339
  year: 2003
  end-page: 345
  article-title: Effect of surgical treatment on the cellular immune response of gastric cancer patients
  publication-title: Braz J Med Biol Res
– volume: 108
  start-page: 308
  year: 2017
  end-page: 315
  article-title: Panel of autoantibodies against multiple tumor‐associated antigens for detecting gastric cancer
  publication-title: Cancer Sci
– volume: 289
  start-page: 31296
  year: 2014
  end-page: 31309
  article-title: Ral GTPase down‐regulation stabilizes and reactivates p53 to inhibit malignant transformation
  publication-title: J Biol Chem
– ident: e_1_2_7_43_1
  doi: 10.1158/1055-9965.EPI-17-0238
– volume: 5
  start-page: 3403
  year: 1999
  ident: e_1_2_7_17_1
  article-title: Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma
  publication-title: Clin Cancer Res
– ident: e_1_2_7_27_1
  doi: 10.1158/1078-0432.CCR-12-0281
– ident: e_1_2_7_51_1
  doi: 10.4049/jimmunol.166.1.678
– volume: 9
  start-page: 5120
  year: 2003
  ident: e_1_2_7_18_1
  article-title: Recursive partitioning as an approach to selection of immune markers for tumor diagnosis
  publication-title: Clin Cancer Res
– ident: e_1_2_7_41_1
  doi: 10.1038/srep25467
– ident: e_1_2_7_48_1
  doi: 10.1007/s12328-017-0749-9
– ident: e_1_2_7_28_1
  doi: 10.2174/092986712803988910
– ident: e_1_2_7_35_1
  doi: 10.1002/cncr.22265
– volume: 23
  start-page: 192
  year: 2007
  ident: e_1_2_7_30_1
  article-title: Serum anti‐p53 antibodies in gastric cancer patients
  publication-title: Pol Merkur Lekarski
– ident: e_1_2_7_32_1
  doi: 10.1074/jbc.M114.565796
– ident: e_1_2_7_42_1
  doi: 10.1002/ijc.27667
– ident: e_1_2_7_14_1
  doi: 10.1111/dote.12206
– ident: e_1_2_7_15_1
  doi: 10.1080/2162402X.2018.1452582
– ident: e_1_2_7_45_1
  doi: 10.1002/ags3.12179
– ident: e_1_2_7_16_1
  doi: 10.1207/S15324796ABM2603_02
– ident: e_1_2_7_12_1
  doi: 10.1158/1078-0432.CCR-08-1086
– ident: e_1_2_7_19_1
– ident: e_1_2_7_4_1
  doi: 10.4143/crt.2016.089
– ident: e_1_2_7_26_1
  doi: 10.1016/j.cell.2012.03.003
– volume: 12
  start-page: 136
  year: 2003
  ident: e_1_2_7_23_1
  article-title: Enhancement of antibody detection in cancer using panel of recombinant tumor‐associated antigens
  publication-title: Cancer Epidemiol Biomarkers Prev
– volume: 2
  start-page: 137
  year: 2008
  ident: e_1_2_7_5_1
  article-title: Current approaches to gastric cancer in Korea
  publication-title: Gastrointest Cancer Res
– ident: e_1_2_7_25_1
  doi: 10.1084/jem.189.7.1101
– ident: e_1_2_7_22_1
  doi: 10.1186/2162-3619-2-15
– ident: e_1_2_7_21_1
  doi: 10.1586/14737159.2015.1035713
– ident: e_1_2_7_29_1
  doi: 10.1002/path.1288
– ident: e_1_2_7_2_1
  doi: 10.3322/caac.21262
– volume: 20
  start-page: 47
  year: 2017
  ident: e_1_2_7_6_1
  article-title: Establishment of risk evaluation model of peritoneal metastasis in gastric cancer and its predictive value
  publication-title: Chin J Gastrointest Surg
– volume: 58
  start-page: 2166
  year: 2011
  ident: e_1_2_7_7_1
  article-title: Predictive value of serum CEA, CA19‐9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer
  publication-title: Hepatogastroenterology
– ident: e_1_2_7_44_1
  doi: 10.1158/0008-5472.CAN-05-3389
– ident: e_1_2_7_31_1
  doi: 10.7717/peerj.3585
– start-page: 18
  volume-title: Classification and Regression Trees
  year: 1984
  ident: e_1_2_7_20_1
– ident: e_1_2_7_47_1
  doi: 10.1007/s00268-008-9821-4
– ident: e_1_2_7_34_1
  doi: 10.1016/S0161-5890(02)00026-3
– ident: e_1_2_7_38_1
  doi: 10.1007/s11060-017-2716-1
– volume: 40
  start-page: 241
  year: 2018
  ident: e_1_2_7_3_1
  article-title: Incidence and mortality of cervical cancer in China, 2014
  publication-title: Chin J Oncol
– ident: e_1_2_7_13_1
  doi: 10.1002/ijc.28807
– ident: e_1_2_7_24_1
  doi: 10.1128/MCB.19.2.1262
– ident: e_1_2_7_9_1
  doi: 10.1586/erm.10.12
– ident: e_1_2_7_10_1
  doi: 10.1111/cas.13158
– volume: 43
  start-page: 417
  year: 1983
  ident: e_1_2_7_37_1
  article-title: Statistical approach to immunosuppression classification using lymphocyte surface‐markers and functional assays
  publication-title: Can Res
– ident: e_1_2_7_49_1
  doi: 10.1158/0008-5472.CAN-03-2646
– ident: e_1_2_7_36_1
  doi: 10.1007/s13277-015-4472-1
– ident: e_1_2_7_46_1
  doi: 10.1002/pros.23217
– ident: e_1_2_7_40_1
  doi: 10.1515/sagmb-2013-0016
– ident: e_1_2_7_39_1
  doi: 10.1073/pnas.111153698
– ident: e_1_2_7_33_1
  doi: 10.1007/s13277-014-1819-y
– ident: e_1_2_7_11_1
  doi: 10.1074/mcp.M115.051250
– ident: e_1_2_7_8_1
  doi: 10.1111/j.1600-065X.2008.00611.x
– ident: e_1_2_7_50_1
  doi: 10.1590/S0100-879X2003000300008
SSID ssj0036494
Score 2.4156992
Snippet The present study aimed to select anti‐tumor‐associated antigen (TAA) autoantibodies as biomarkers in the immunodiagnosis of gastric adenocarcinoma (GAC) by...
The present study aimed to select anti‐tumor‐associated antigen ( TAA ) autoantibodies as biomarkers in the immunodiagnosis of gastric adenocarcinoma ( GAC )...
The present study aimed to select anti-tumor-associated antigen (TAA) autoantibodies as biomarkers in the immunodiagnosis of gastric adenocarcinoma (GAC) by...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1829
SubjectTerms Adenocarcinoma
Adenocarcinoma - diagnosis
Adenocarcinoma - immunology
Adult
Aged
Aged, 80 and over
Antigen (tumor-associated)
Antigens
Antigens, Neoplasm - blood
Antigens, Neoplasm - immunology
Autoantibodies
Autoantibodies - blood
Autoantibodies - immunology
autoantibody
biomarker
Biomarkers
Biomarkers, Tumor - blood
Biomarkers, Tumor - immunology
Cancer therapies
Carbohydrates
Case-Control Studies
Enzyme immunoassay
Esophagus
Female
Gastrectomy
gastric adenocarcinoma
Gastric cancer
Humans
Immunodiagnosis
Immunoglobulins
Immunologic Tests - methods
Lymphatic system
Male
Medical prognosis
Metastases
Metastasis
Middle Aged
Mortality
Multivariate Analysis
Original
p53 Protein
Patients
Prediction models
PTEN protein
recursive partitioning approach
ROC Curve
Statistical analysis
Stomach Neoplasms - diagnosis
Stomach Neoplasms - immunology
Studies
Surgery
tumor‐associated antigen
Young Adult
SummonAdditionalLinks – databaseName: Wiley Online Library - Core collection (SURFmarket)
  dbid: DR2
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEB6CD6WXNH2kVZOGbekhF5m1tNJa9BRMTCikh7YBHwJC-2pNGilYMoSc-hP6G_tLOrN6ENctlN4MGrOS9pvZb1az3wC8nWBWNU14EVrrRChiZcKMqyzEvE1xoy03EzrvfP4hPbsQ7xfJYgfe9WdhWn2IYcONPMPHa3LwQtX3nJxagvnsAOMv1WoRIfo4SEfFqcjahrZC4uhx1KkKURXP8M_NtWiLYG7XSd7nr34Bmj-Cy_7W27qTq_G6UWN995uq438-2x7sdsSUnbRIegw7tnwCD867T-9P4dYXF7AV7c9TyTu7IdB127mslyZnTcVq31qHNevravXz-4-iA4A1DGeRxD9rtizZkg6mVKat9FvWrHLsS0FNRDQrMBbiErvCgavr4hlczE8_z87Crm1DqJE7xmGmMpdoZBoSU-_UJSZ1Bl2dcyN5phwmOFJrXDsVzo2TGDKERmBoY0goW8hpvA-jsirtC2BSy8i5dKpMnAhM9aaR4dJNImuE1kgdAzjuJzDXnaY5tdb4lve5Db7J3L_JAN4MpjetkMefjA57FOSdL9c5khwMwhGCKIDXw2X0Qvq0UpS2WpMNF3TWJuIBPG9BM4wSI4sliZ4A5AacBgNS-N68Ui6_eqXvFPNHJBD4mB4tf7_xfHbyyf94-e-mB_AQ2V_W1r0dwqhZre0rZFiNOvKu9AsAPyW0
  priority: 102
  providerName: Wiley-Blackwell
Title Using recursive partitioning approach to select tumor‐associated antigens in immunodiagnosis of gastric adenocarcinoma
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcas.14013
https://www.ncbi.nlm.nih.gov/pubmed/30950146
https://www.proquest.com/docview/2247632903
https://www.proquest.com/docview/2204686220
https://pubmed.ncbi.nlm.nih.gov/PMC6550128
Volume 110
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NattAEB4aG0ovJf1X65pt6aEX0bW00lqnkISYUEgIaQO-CWl_GkMjuZYNPfYR-ox9ksysVkpMmlyEQAuSdmZ2vpmd_Qbg0wSjqmnCi9AYK0IRlzrMeJmFGLeVXCvD9YTOO5-cpscX4us8mfuEW-PLKrs10S3UulaUI_-CrgZNIcp4vLf8FVLXKNpd9S00dmBI1GWk1XLeB1xxKrK2qa2Q-AVx5JmFqJKHGoq52GLbH90BmXdrJW9jWOeEZrvw1KNHtt-K-xk8MtVzeHzi98dfwG9XAcBWlESnunS2JM3wOVfW8Yezdc0a1_-GrTdX9erfn7-Fl5LRDKeaGDobtqjYgk6P1Lotx1s0rLbsR0GdPhQrcMFCP7jCF9dXxUu4mB19PzwOfW-FUCHAi8OszGyiEA5IjI9Tm-jUarRHzrXkWWkxCpFKoYMrcfKsRLsWCqWntCY2ayGn8SsYVHVl3gCTSkbWptNSx4nAeGwaaS7tJDJaKIX4LoDP3QznyhOPU_-Ln3kXgKAwcieMAD72Q5ct28b_Bo06MeXe4Jr8Rj0C-NA_RlOh_Y-iMvWGxnBBB2IiHsDrVqr9W2KEmsSjE4Dcknc_gGi4t59Ui0tHx51ikIdeHn_Tacb9H54f7n9zN28f_oN38ARhWdYWpI1gsF5tzHuEPutyDDuROBs7LR_D8ODo9Ox87NIIdD2PrgGhHQow
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwEB6VVgIuFeWnBEoxCCQuUb2JE28OCFUt1ZZ2e6GV9hYS_5SVaLJsdlV66yP0SfpQPAkzzg-sCtx6W8nWJs589nyfPZ4BeNNDVdWPeOYbY4Uvwlz7Cc8TH3VbzrUyXPfovvPwKB6ciE-jaLQE1-1dGAqrbNdEt1DrUtEe-Ra6GpwKQcLDD5PvPlWNotPVtoRGDYsDc3GOkq16v7-L9n0bBHsfj3cGflNVwFdIbUI_yRMbKXSEEpVhbCMdW41I5FxLnuQW-bdUCpf2vBcKKxHRQuF7K60pj7OQ_RD_9w6soOPlJPbkqBN42JzURXSFxBGHQZPJiCKHqICZ0zKL_u8Gqb0Zm_knZ3ZOb-8BrDZslW3X8FqDJVM8hLvD5jz-EfxwEQdsSpv2FAfPJoTEZo-XtfnK2axklau3w2bzs3L68_Iqa1BhNEPTUkbQio0LNqbbKqWuw__GFSstO82osohiGS6Q6Hen-ODyLHsMJ7fy1Z_AclEW5ikwqWRgbdzPdRgJ1H_9QHNpe4HRQinkkx68a79wqppE51Rv41vaCh40RuqM4cHrruukzu7xt04brZnSZoJX6W84evCqa8apSectWWHKOfXhgi7gBNyD9dqq3VNCpLaUt8cDuWDvrgOl_V5sKcZfXfrvGEUlsgocpkPGv1883dn-7H48-_8IXsK9wfHwMD3cPzp4DveREiZ1MNwGLM-mc_MCadcs33RYZ_DltifXL6aBQLI
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwEB6VrVRxQfyTUsAgkLhE9SZOvDkgVNquWkpXFVCptzTxD6zUJstmV8CNR-B5eByehBnHWVgVuPUWKaMkzsx4vs8ezwA87SOrGiS8CI2xIhRxqcOMl1mIvK3kWhmu-3Te-XCU7h2L1yfJyQr86M7CUFplNye6iVrXitbINzHUoCtEGY83rU-LONoZvpx8CqmDFO20du00WhM5MF8_I31rXuzvoK6fRdFw9_32Xug7DIQKYU4cZmVmE4VBUSJLTG2iU6vRKjnXkmelRSwulcJpvuzHwkq0bqFwDEprquks5CDG516BVUmsqAerr3ZHR2-7OIACWdtSV0gcfxz5ukaUR0TtzByzWY6GFyDuxUzNPxG0C4HD63DNY1e21RrbDVgx1U1YO_S787fgi8s_YFNawqeseDYhu_QrvqyrXs5mNWtc9x02m5_X05_fvhfeRoxmqGiqD9qwccXGdHal1m0y4LhhtWUfCuozoliB0yVG4Sm-uD4vbsPxpfz3O9Cr6srcAyaVjKxNB6WOE4FscBBpLm0_MloohegygOfdH86VL3tO3TfO8o7-oDJyp4wAnixEJ22tj78JbXRqyr27N_lv4wzg8eI2OirtvhSVqeckwwUdx4l4AHdbrS7eEiPQpSo-AcglfS8EqAj48p1q_NEVA0-RYiLGwGE6y_j3h-fbW-_cxfr_R_AI1tCx8jf7o4P7cBXxYdZmxm1AbzadmweIwWblQ2_sDE4v279-AfjBRk0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Using+recursive+partitioning+approach+to+select+tumor-associated+antigens+in+immunodiagnosis+of+gastric+adenocarcinoma&rft.jtitle=Cancer+science&rft.au=Qin%2C+Jiejie&rft.au=Wang%2C+Shuaibing&rft.au=Shi%2C+Jianxiang&rft.au=Ma%2C+Yan&rft.date=2019-06-01&rft.eissn=1349-7006&rft.volume=110&rft.issue=6&rft.spage=1829&rft_id=info:doi/10.1111%2Fcas.14013&rft_id=info%3Apmid%2F30950146&rft.externalDocID=30950146
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-9032&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-9032&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-9032&client=summon